StemCell Therapy

Genetic testing

TheHuman Genome Projectled to the discovery of thousands of disease genes. Genetic testing can help patients determine disease risk and the likelihood of passing on or inheriting certain disorders.

Learn more aboutgenetic testingand how to use this information in your practice.

LINKS 1-6: Topics in genetics & personalized medicine

Genetic testing is expected to become a routine part of patient care in the future, but unless this DNA information is protected, the potential grows for discrimination against people based on their genetic information.

Understand more aboutgenetic discrimination.

LINKS 1-6: Topics in genetics & personalized medicine

Gene patentingis a broad term referring to the patenting of genetic sequences such as DNA and RNA, and to alternative forms of DNA such as cDNA (complementary DNA).

Learn more aboutgene patentingand its impact on patient care.

LINKS 1-6: Topics in genetics & personalized medicine

Direct-to-Consumer (DTC) genetic tests are marketed and sold directly to consumers, and do not require the assistance of a physician or other health care provider to obtain or interpret.

Learn aboutDTC genetic tests.

LINKS 1-6: Topics in genetics & personalized medicine

Precision medicine is a tailored approach to health care that accounts for the individual variability in the genes, environment and lifestyle of each person.

Learn more aboutprecision medicineand the President's Precision Medicine Initiative.

LINKS 1-6: Topics in genetics & personalized medicine

Go here to read the rest:
Selected topics in genetics & personalized medicine ...

Cancer Genomes

Cancer is a genetic disease. It starts with one unlucky cell that loses control over growth and division and evades the immune system; it continues with accumulation of mutations in the genome of its progeny that make them grow even faster; and it eventually reaches the point where it is detected by a physician. SCGPM researchers are devising new approaches to study genomic changes in cancers, to understand cancer origins and progression, and to determine which altered genes might be developed into drug targets.

The human brain has 100 billion neurons that govern how we think, feel, learn, and remember. Defects in the formation of these neurons during development can lead to mental retardation, and during aging or in diseases such as Alzheimer's, there is a decline in cognitive function, particularly memory. SCGPM scientists are identifying the molecular changes that occur in brain cells during development, aging, and diseases. Identifying these molecular changes will provide new avenues to ameliorate neurological diseases and to prevent age-dependent decline in cognitive function.

SCGPM scientists are investigating the genetic basis of Mendelian, oligogenic, and complex human cardiovascular diseases employing high-throughput sequencing of informative families and association-based whole genome scanning methodologies with large case-control cohorts. Causal genetic variation identified through these approaches is under investigation to elucidate the mechanistic basis for the disease associations.

See the article here:
SCGPM | Stanford Center for Genomics and Personalized ...

About Conference

Euro Personalized Medicine 2019Conference welcomes the Professors, Pathologists, Specialists,Clinical Geneticist, Cytogenetic Diagnostics, Therapists, Researchers Specialized from Molecular Genetics and Genomics, Physicians and Hospitalists with different specialties such as Endocrinologist, Cardiologist,Nephrologist, Orthopaedic, Haematologists, Immunologists,Oncologists, Rheumatologist, Research scholars, Industrial professionals and Student delegates from Biomedical, Pharmaceuticals and Telemedicine and Healthcare Sectors to be a part of it, from all over the world to Rome Italy . We are delighted to invite you all to attend and register at 10thEuropean Conference on Predictive Preventive and Personalized Medicine & Molecular Diagnostics " which is going to be held during August 29-30, 2019, in London UK.

The theme of the conference isExploring Innovations in advancing Personalized Medicine and Bio-Markers.Euro Personalized Medicine is a multidisciplinary field, interesting and interactive scientific sessions have been designed accordingly for this conference which includes the diagnosis, care and management of different acute and chronic medical conditions, comprises of various medical specialties such as cardiac health issues, brain disorders, digestive diseases, blood disorders, respiratory diseases, different types of cancers , immunological andinfectious diseases, basically all minor and major health issues which requires short and long-term, comprehensive care.

The organizing committee is gearing up for an exciting and informative conference program including plenary lectures, symposia, workshops on a variety of topics, poster presentations and various programs for participants from all over the world. We invite you to join us at the Euro Personalized Medicine -2019, where you will be sure to have a meaningful experience with scholars from around the world. All members of the Euro Personalized Medicine-2019 organizing committee look forward to meeting you in Euro Personalized Medicine -2019.

Conference Series Ltd has an enhanced and highlighted features of scientific partnerships and alliances with development agencies, Institutes, leading research organizations, non-government organizations, and other entities to promote the development-oriented research acrossthe globe through live streaming, B2B and Scientific Meetings. Conference Series LtdsMedical Conferencesprovides an excellent opportunity for the budding scientists and young researchers through its special initiatives like Young Researcher Forum, Poster Presentation and E-poster. Conference Series Ltd Organizes 300+Scientific Conferencesevery year across USA, Europe & Asia. Besides 500 Peer reviewed, Open Access Journals, Conference Series Ltd has collaborated with more than 1000Scientific Associationsand institutions worldwide to promote information on health care and technologies. These journals are enjoying the support of over 5 million readers; a team of 30.000 eminent scholars is providing editorial support.

Importance and scope:It estimated that 57 countries have an absolute shortage of 2.3 million physicians and nurses, midwives. This shortage of primary health care professionals suggests that many countries have insufficient numbers of health professionals to deliver essential health interventions. The shortage is defined as having a projected supply of primary physicians that meet less than 80% of the forecasted primary care demand or need, calculated at estimated means.

Who is Attending?

WHAT IS IT?

Preventive Medicine

Preventive healthcare consists of measures taken fordisease prevention, as opposed to disease treatment. Amedicineor other treatment designed to prevent disease or ill healths. Which is affected by environmental factors, genetic predisposition, disease agents, and lifestyle choices

Predictive Medicine

The branch of medical science or practice concerned with the prediction of the occurrence or course of disease in individual patients, now especially usinggeneticinformation.

Molecular diagnostics

Molecular diagnostics method used to analyzebiological markersin the genome and proteome and by applying molecular biology to medical testing. This technique is used to diagnose and monitor disease, detect risk, and decide which therapies will work best for individual patients.

Personalized medicine

Personalized medicineis amedicalpractice that separates patients into different groups withmedicaldecisions, practices, interventions, and products being tailored to the individual patient based on their predicted response andrisk of disease.

Personalized Medicinealludes as an individualized treatment which implies the solution of particular medications and therapeutics. Personalized Medicine 2019 highlights the topic"Exploring Innovations in advancing Personalized Medicine and Bio-Markers"alongside the logical system clears an approach to assembling visionaries through the exploration talks and presentations. A definitive mission of the meeting is to advance numerous interesting the Novel Approaches and Innovations in customized prescription and social insurance, serves a motivation for the progression ofMolecular Diagnostics, a brief talk on Protein Biomarkers, extraordinary spotlight onGeneticsInformed PersonalizedImmunotherapyandStem CellsTherapy as the Future of Personalized Medicine. Customized Medicine guarantees numerous restorative advancements, and can possibly change the way medications are found and utilized.

Conference Series Ltdis devotedly involved in conducting 300+Conference Series Ltd Every Year across Europe, USA (Baltimore, Chicago, Las Vegas, Philadelphia, and San Antonio) and almost all other parts of the world with support from 1000 more scientific societies and Publishes 400+ Open access journals which contains over 30000 eminent personalities, reputed scientists as editorial board members.

Personalized medicine therapeuticsand companion diagnostic market have huge opportunities for growth in healthcare and will improve therapeutic effectiveness and reduce the severity of adverse effects approach todrug therapies. Personalized cancer medicine is self-made samples of translating cancer genetics into medical. There is a huge contribution ofGenomic medicineby revealing genomic variations; have an effect on health, sickness and drug response.Biomarkeralso plays vital role in the biological characteristic which can be molecular, anatomic, physiologic and chemical change drug development research which turns biomarkers intocompanion diagnostics.

Benefits of Attending the Conference

Supporting Journals:

Contact Person:

Andriana Samron

Program Manager | Euro Personalized medicine 2019

Phone:1-702-508-5200 x 8036

The 10thEuropeanConference onPredictive Preventive and Personalized Medicine & Molecular Diagnostics will be held on August 29-30, 2019 in London, UK will be organized around the themeExploring Innovations in advancing Personalized Medicine and Bio-Markerswhichcomprises 23 Sessions/Tracksto outline the theme of the conference organized byconference series llc LTDConferences. The main aim of the conference is to highlight the achievements and innovations in the various fields of Personalized Medicine across the globe.

Track 1:Molecular Diagnostics in Personalized Medicine

In personalized medicinemolecular diagnosticsis used for analysing of biological markers and also analysing by applying molecular biology to medical testing .This technique is used to diagnose and monitordisease, detect risk in individual patients .DNA sequencing is the process of determining the precise order of nucleotides within a DNA molecule .SNP genotyping is the measurement ofgeneticvariations of single nucleotide polymorphism (SNPs).which is the measurement of more generalgeneticvariation. Gene expression profiling is used for the measurement ofthe activity of thousands of genes at once.

Related Associations:

Alzheimers and Dementia Testing for Earlier Diagnosis

Association for Molecular Pathology Establishes New Standard for Clinical Utility of Molecular Diagnostics

British In Vitro Diagnostics Association (BIVDA)

California Life Sciences Association- Molecular Diagnostics

American Board of Clinical Chemistry

Molecular Diagnostics Laboratory

Association for Molecular pathology

Track2:Biomarkers Personalized Medicine

In personalized medicinebiomarkersand biological markergenerally refers to a measurableindicator of some biological state or condition. This wordrefers to a substance the presence of which indicates the existence of aliving organism. Biochemical biomarkers are often used inclinical trials, Biomarkers used forpersonalized medicineare typically categorized as either prognostic or predictive .In, a biomarkersis a molecule that allows the detection and isolation of a particular cell type. Abiomarkerindicates a change instate of a protein that correlates with the risk or progression of a disease . Biomarkers are useful in a number of ways, including measuring the progress ofdisease. Biomarkers also used inearlydiagnosis, disease prevention, drug target identification, drug response etc.

Related Associations:

ALS research Association

European society of cardiology

American Association of Pharmaceutical Scientists

American Board of Clinical Chemistry

Track3:Pharmacogenetic in Personalized Medicine

In personalized medicinepharmacogeneticsis the study of inherited genetic differences in drug metabolic pathways which can affect the drug responses, like therapeutic effect as well as adverse effect. Inter- and intra-individual variation ingene expressionand its function.In oncology,pharmacogeneticsrefers to germline mutations andpharmacogenomicsis study the somatic mutations in tumoral DNA leading to alteration in drug response

Related Associations:

European Society of Pharmacogenomics and Personalized Medicine

American Society of Human Genetics

Hungarian Society of Personalized Medicine

American Society for Investigative Pathology

Association for Molecular Pathology

Track4:Pharmacogenomics in Personalized Medicine

Pharmacogenomicsis the study of the role of genetics in drug response. It deals with the influence of acquired and inheritedgeneticvariation on drug response, drug absorption distribution, metabolism, and elimination ,as well as drug receptor target effects .Pharmacogenomicsis often used interchangeably with pharmacogenetics.Pharmacogenomics is used for the detection of the individualgeneticvariation with drug responsespharmacogeneticsfocuses on single drug-gene interactions, incorporatinggenomicsand epigenetics while dealing with the effects of multiplegeneson drug response

Related Associations:

Genetics societies

Canadian Association of genetics Counsellors

European Cytogeneticists Association

Human genome organization

International Genetic Epidemiology Society

British Society of Genetic Medicine

Track5:Pharmacoproteomics in Personalized Medicine

Theproteomeis the entire set ofproteinsit is expressed by genome , cell, tissue, or organism at a certain time. More specifically, it is a combined of proteins and genomes .Proteomicsis the study of the proteome. Acellularproteome is the collection of proteins present in a particularcelltype and it exposure to harmone stimulation . It can also be useful to consider an organisms complete proteome, which can be conceptualized as the complete set of proteins from all of the various cellularproteomes. Proteome used to refer to the collection of proteins in certain sub-cellularbiological systems.

Related Associations:

International precision medicine Associates

International Society of Personalized Medicine

British Society for Proteome Research

European Proteomics Association

Swiss Proteomics Society

Japan Society for clinical Proteomics

Track6:Metabolomics in Personalized Medicine

Metabolomicsis defined as the chemical processes involving of metabolites. Metabolomics is the study of the unique chemical fingerprints. Themetabolomerefers to the collection of all metabolites in a biological cell, tissue, organ or organism. mRNA gene expression data and proteomic analyses reveals the set of gene products in the cell. One of the challenges of system biology and functional genomics is to integrate proteomic ,transcriptomic, andmetabolomicinformation to provide acellular biology.

Related Associations:

Metabolomics Society

The Metabolomics Standards Initiative (MSI)

Metabolomics for a Low Carbon Society (METABOLOMICS)

Swiss Metabolomics Society

Metabolomics Research Group (MRG)

Track7:Personalized in Health Care

Personalized medicineis aMedical Practicethat separates patients into different groups with medical decisions, practices, interventions and products being tailored to the individual patient based on their predicted response or risk of disease. The words of personalized medicine,precision medicine,stratified medicineand P4 medicine are used interchangeably .

Related Associations:

American Health Care Association

Florida Health Care Association

OHCA Oregon Health Care Association

Texas Health care Association

Washington Health Care Association

Track8:Non- genomics Personalized Medicine

Epigenomicsis a set of epigenetic modifications on the genetic material of a cell is called as the epigenome. Epigenetics are reversible modifications on a cells DNA that affect the gene expression without altering the DNA sequence.Epigeneticmodifications are important role in the gene expressionand regulation, that are involved in the numerouscellularprocesses such as tumorigenesis.

Related Associations:

Genome Wide Association Studies (GWAS)

Genetics societies

Canadian Association of genetics Counsellors

European Cytogeneticists Association

Human genome organization

International Genetic Epidemiology Society

British Society of Genetic Medicine

German society of Human Genetics

Track9:Personalized Biological Therapies

Biological therapyrefers to the use of medication , specifically target an immune orgeneticmediator of disease. Even for diseases of unknown cause of molecules that are involved in the disease process have been identified, and can be targeted for biological therapy. which are mainly cytokines , are directly involved in the immune system .Biological therapyused for the management of cancer , autoimmune disease, and diseases of unknown cause that result in symptoms due to immune related mechanisms.

Read more here:
Euro Personalized Medicine Conferences 2019 | Molecular ...

Genomic medicine has long offered the promise of gene-based disease prevention and treatmentallowing medical providers to successfully predict, prevent, and treat disease based upon an individuals genetic or biomarker information. And while we are a long way from the fountain of youth, personalized medicine, also known as precision medicine, is no longer a future-situated hypothetical; many physicians even offer genetic testing at routine wellness visits. But personalized medicine triggers a host of questions for life sciences companies to sort through (i.e. manufacturing, commercializing, etc.), not the least of which pertain to quality and regulatory concerns.

While the practice of medicine has always been personalizedindividual patients treated based on their health profiles and disease markersthe evolving field of personalized and precision medicine involves more refined diagnostic testing than traditional medicine. And treatment is tailored to the patient after accounting for the patients unique biological, physiological, and environmental profiles. As defined by the International Society for Pharmacoeconomics and Outcomes Research (ISPOR), personalized medicine is the use of genetic or other molecular biomarker information to improve the safety, effectiveness, and health outcomes of patients via more efficiently targeted risk stratification, prevention, and tailored medication and treatment management approaches.

But given the departure from one-size-fits-all or trial and error diagnostic and treatment models, unique quality assurance challenges arise. For instance, how can adverse event tracking models apply to highly tailored treatments specific to each patients unique biology? How can clinicians and pathologists ensure that specimens remain valid and reliable throughout processing? And how will companies absolutely ensure the safety of protected health information that will increasingly include patients individual genetic code? These questions are generating a lot of buzz in the world of personalized and precision medicine and will continue to do so in the coming years.

Ironically, though the prevalence of adverse events theoretically decreases with the targeted provision of personalized medicine, a new problem of tracking adverse events emerges. While adverse event tracking in traditional medicine involves large sets of variable data, in personalized medicine, the number of variables is vastly increased.

Sophisticated big data analytics will continue to play an important role in adverse event detection, developing efficient flows of information and complex algorithmic solutions to assist pharmaceutical and biotech companies as well as regulators in successfully interacting with adverse event data.

A celebrated tenet of personalized medicine is that only treatments likely to benefit the patient are administered. But it was discovered that unreliable specimens led to inaccurate HER2 tests in up to 20 percent of cases, leading to inappropriate breast cancer treatment decisions. As a result, guidelines were established to ensure proper specimen-handling. However, such guidelines are not the norm vis--vis specimen processing and there is generally a lack of standardization as specimens travel from patient to pathologist.

As this issue becomes more visible, watch for further guidance from the following authorities: the American Society of Clinical Oncology (ASCO) as well as other professional organizations; the World Health Organization (WHO); the FDA; and the Centers for Medicare and Medicaid Services (CMS).

Another challenge for pharmaceutical and other life sciences companies is anticipating the regulations related to personalized healthcare, including gene and cell therapy. As human cell and gene therapy-related research and development rapidly expands, all stakeholders must watch for equally rapid shifts in regulations.

For the third year in a row, more than 25% of all new molecular entities (NMEs) approved by the FDAs Center for Drug Evaluation and Research (CDER) in 2016 were personalized medicines. And July 2017 saw the FDAs approval of Kymriah, Novartis CAR-T gene therapy, indicating the FDAs readiness to support personalized medicine. However, with novel biologic products comes minimal long-term evidence of safety and efficacy as well as a dearth of treatment experience. This doesnt help in alleviating uncertainty around the future of regulatory action and market viability of such personalized treatments.

Lately, many international workshops have convened to address the emerging regulatory issues pertaining to cell therapy while regulatory bodies have published guidance for cell therapy productsincluding several guidance documents added by the FDA in late 2017.

The well-known provision for real world evidence (RWE) in the recent 21st Century Cures Act (the Cures Act) has the potential for a major impact on the approvals of personalized medicine products. Given the non-traditional treatment profile of a gene therapy, RWE is especially helpful in assessing personalized medicines long-term benefits and risks in clinical practice. Under the sixth installment of the Prescription Drug User Fee Act (PDUFA VI), the FDA has committed to speeding the drug approval process by hiring more highly qualified experts as well as facilitating a more well-established use of real-world evidence to support post market drug safety surveillance by instating a new safety review system.

As with many emerging technologies, the enthusiasm surrounding personalized medicine is tempered by uncertainties in quality and regulatory schemas. As the shift to personalized medicine is younger than the laws that otherwise regulate the medical and research fields, there are frustrating gaps between technology and oversight. But these gaps should narrow while companies continue to make reasonable assumptions while they wait. As always, all stakeholders must remain vigilantly abreast of quality and regulatory developments as personalized medicine shows promise as the future of healthcare. Vigilance is of particular import to the many smaller developers of personalized medicines that may have limited resources or regulatory support.

Stakeholders must remember that regulatory views differ on a global basis, including between the FDA and the EMA. We expect a common set of principles to emerge as personalized medicine continues to secure its foothold as an accepted field of medical treatment.

If you found this information interesting, subscribe to our blog to receive the latest insights, like this one:

Excerpt from:
Personalized Medicine: Quality and Regulatory Issues

PhRMAs member companies are on the leading edge of personalized medicine development an area that is transforming health care, improving patient outcomes and creating health system efficiencies. In a new video, Dr. Bernie Zeiher, president of development of Astellas, discusses his excitement around the promise of personalized medicine, which uses diagnostic tools to help assess the medical treatments and procedures that may be best for each patient.

I am very optimistic about the future because the promise of personalized medicine has begun to be seen, Dr. Zeiher says in the video. Now, with more personalized-type therapies, you can test the tumor or test the blood to determine that in fact the person has a particular mutation, and then that will guide which therapy you would choose and it also increases the likelihood that the patient will respond.

Dr. Zeihers enthusiasm reflects the commitment of Americas biopharmaceutical companies to the development of these targeted treatments. Although there were only 13 FDA-approved personalized medicines in 2006, today there are more than 140. Additionally, personalized medicines accounted for more than 25 percent of FDA approvals last year, marking a record year for these innovative therapies.

Cancer is an area where personalized medicines are having a particularly big impact, driving tremendous advances for patients with highly aggressive cancers, like non-small cell lung cancer (NSCLC). In fact, research has shown nearly two-thirds of NSLCs have a genetic mutation that can be more effectively targeted with a personalized medicine.

Thanks to the hard work of biopharmaceutical researchers, like Dr. Zeiher, 42 percent of medications currently in the pipeline have the potential to be personalized. While the science has never been more complex, the future of research is bright with personalized medicine becoming a reality.

Read the rest here:
The Promise of Personalized Medicine | Innovation.org

Research can take a long time; therefore, we cannot guarantee that we will find information in your sample to return to you. As more samples are processed and genotyping is completed, the Biobank may find information that is medically important for some participants. This information is about genetic variations or changes in DNA that may affect how a person reacts to certain types of medications or that may increase risk of certain diseases, such as cancer or heart disease. For many of these diseases, there are medical options to reduce risk or manage the effects of disease.

If we learn something about your sample, such as information on your risk of certain diseases or health conditions, how you may respond to medications or your risk of being a carrier of certain diseases, we may be able to return this to you. We will ask your permission first before returning any information to you. However, not everyone will have this information, so we cannot guarantee that everyone will receive results

See original here:
Colorado Center for Personalized Medicine

Personalized medicine is gaining recognition due to limitations with standard diagnosis and treatment; many areas of medicine, from cancer to psychiatry, are moving towards tailored treatment for individual patients based on their genetic signatures and clinical characteristics. Advances in whole genome sequencing have allowed the identification of genes involved in a large number of diseases, and biomarkers that indicate disease severity or susceptibility to treatment are increasingly being characterized. The continued identification of new genes and biomarkers specific to disease subtypes and individual patients is essential for translation into personalized medicine, in terms of estimating both disease risk and response to therapy. This article collection covers recent advances in personalized medicine across all areas of medical science and clinical practice, demonstrating that patient-tailored treatment is being employed for some diseases, whereas more work is required to translate scientific advances into the clinic for others. We are seeking submissions of original research, reviews and debates offering insights into new advances in this exciting area of medicine.

Read the original:
Personalized medicine: genes, biomarkers and tailored treatment

Personalized medicine are drugs that are based on individual patient or intended patient groups carrying certain biomarkers and are created to cater the requirement of an individual patient based on the response produced by the patient suffering from a particular disease. The personalized medicines are currently in focus due to their effectiveness in cancer patients and patients suffering from rare genetic disorders. The fact that this approach could do away with the One Size Fits All approach leads to anticipations regarding higher treatment effectiveness through customization of prevention, prediction and treatments. In this regard, funds worth EUR 1 Bn has been invested by the EU as of 2015, focused on the development of personalized medicine, through its Seventh Framework Program for Research and Technological Innovation. The EU is also known to be coordinating with the member states on Health Technology Assessment for better understanding on cost-benefit-efficiency of including personalized medicines in their respective health systems. Constructive dialogue among global stakeholders could streamline the clinical trial processes and regulations regarding the same over the forthcoming years.

Personalized Medicine Market: Drivers & Restraints

Personalized medicine market is expected to witness rapid growth due to increasing disease incidence and deep focus of creating medicines for cancer patients where effectiveness has been proved to be higher as compared to other therapies. Rapid results & customized effects, lower probability of medication flaws and adverse drug reactions are some of the other factors that could create suitable traction in both R&D and revenue potential for these medicines. Favorable policies of the governments in relation to the personalized medicine will also add incremental opportunity to exploit this market. Recent developments in the pharmacogenomics are expected to create suitable environment for developing drugs, which are specific to one patient or group. Development of genetic databases could provide additional boost to the market. Upcoming therapeutic application opportunities in fields such as cardio-renal, neurology, antiviral, pulmonary, psychiatry among others could create R&D traction across all regions.

Complex nature of the drugs, high development costs, sub-optimal development framework and inter-patient variability of effects are some of the restraints that could hamper revenue growth of the personalized medicines market over the forthcoming years.

Personalized Medicine Market: Segmentation

This market can be segmented on the basis of Therapeutic area, End user and Application as follows:

Segmentation based on Therapeutic area

Oncology

Neurology

Cardiology

Antiviral

Psychiatry

Others

Segmentation based on End User

Hospitals

Molecular Diagnostic Laboratories and Testing facilities

Academic Institutes, clinical care and Research Laboratories

Contract Research Organizations

Bio and health informatics companies

Others (Service providers, partners, venture capitalists, etc.)

Segmentation based on Application

Companion Diagnostics

Biomarker identification

Health Informatics

Clinical Research

Personalized Medicine Market: Overview & Region wise Outlook

This market is mainly driven by increasing disease incidence of various cancers and other autoimmune diseases during the forecast period. The major growth in revenues is estimated to be contributed by markets in North America followed by Europe. This can be attributed to increasing pool of cancer patients along with high healthcare per capita expenditure. The ongoing research and legal initiatives in personalized medicine in Japan could promote the market growth in the country during the forecast period. In markets in Asia pacific and Latin America regions, accelerated development of R&D infrastructure could lead bigger drug makers to create their regional R&D centers focused on personalized medicine during the forecast period. The opening up research in the bioinformatics industry and active peer levels discussion and dialogues are factors that contribute to sustainable growth of the personalized medicines market in the medium to long term.

Personalized Medicine Market: Key Players

Some key players in this market are Roche Holding AG, Astra Zeneca PLC, Vertex Pharmaceuticals Inc., Qiagen Inc., BD (Becton Dickinson & Co., Merck & Co. Inc., Pfizer Inc., American Association for Cancer Research, Siemens Healthcare Diagnostics, Inc. among others.

The research report presents a comprehensive assessment of the market and contains thoughtful insights, facts, historical data, and statistically supported and industry-validated market data. It also contains projections using a suitable set of assumptions and methodologies. The research report provides analysis and information according to categories such as market segments, geographies, types, technology and applications.

The report covers exhaustive analysis on:

Regional analysis includes

North America (U.S., Canada)

Latin America (Mexico. Brazil)

Western Europe (Germany, Italy, France, U.K, Spain, Nordic countries, Belgium, Netherlands, Luxembourg)

Eastern Europe (Poland, Russia)

APEJ (China, India, ASEAN, Australia & New Zealand)

Japan

Middle East and Africa (GCC, S. Africa, N. Africa)

The report is a compilation of first-hand information, qualitative and quantitative assessment by industry analysts, inputs from industry experts and industry participants across the value chain. The report provides in-depth analysis of parent market trends, macro-economic indicators and governing factors along with market attractiveness as per segments. The report also maps the qualitative impact of various market factors on market segments and geographies.

Report Highlights:

Detailed overview of parent market

Changing market dynamics in the industry

In-depth market segmentation

Historical, current and projected market size in terms of volume and value

Recent industry trends and developments

Competitive landscape

Strategies of key players and products offered

Potential and niche segments, geographical regions exhibiting promising growth

A neutral perspective on market performance

Must-have information for market players to sustain and enhance their market footprint.

NOTE -All statements of fact, opinion, or analysis expressed in reports are those of the respective analysts. They do not necessarily reflect formal positions or views of Future Market Insights.

Follow this link:
Personalized Medicine Market - Global Industry Analysis, Size ...

November 14 15, 2018 Harvard Medical School, Boston, MA

We need to make the transition to a predict, prevent and protect health system.

Joshua Ofman, M.D., M.S.H.S.Senior Vice President, Global Value, Access and Policy, Amgen

*** Speakers will be added to the schedule on a rolling basis as they are confirmed. ***

7:00 a.m.

Registration and Continental Breakfast

Joseph B. Martin Conference Center at Harvard Medical School77 Avenue Louis Pasteur, Boston, MA 02115

8:00 a.m.

Opening Remarks

SPEAKER | Edward Abrahams, Ph.D., President, Personalized Medicine Coalition

8:10 a.m.

Setting the Stage: Exploring the Promise of Personalized Medicine A Keynote Address

SPEAKER | Elizabeth Nabel, M.D., President, Brigham and Womens Hospital

8:55 a.m.

Shifting Systems: Identifying the Common Challenges and Notable Achievements of Government Efforts to Advance Personalized Medicine

Government executives have an enormous influence over the direction of health systems and can therefore play a role in developing personalized medicine but they need to know what works and what doesnt if their respective efforts to promote personalized medicine are going to succeed. With that in mind, government representatives from around the globe will discuss the competitive advantages various countries have in personalized medicine and explore the common challenges and notable achievements of government initiatives to advance the field during this panel discussion.

MODERATOR | Antonio L. Andreu, M.D., Ph.D., Scientific Director, EATRIS European Infrastructure for Translational Medicine

Ora Dar, Ph.D., Senior Expert, Medical Sciences, consultant to the Israel Innovation Authority

Tom Fowler, Ph.D., Deputy Chief Scientist, Genomics England

Marc LePage, President, CEO, Genome Canada

Liisa-Maria Voipio-Pulkki, M.D., Ph.D., Director General, Chief Medical Officer, Ministry of Social Affairs and Health, Finland

10:10 a.m.

Networking Break

Light refreshments provided.

10:40 a.m.

Evaluating Patients Priorities: Understanding Perspectives on Personalized Medicine A Fireside Chat

MODERATOR | Susan McClure, Founder, Publisher, Genome magazine; Board Member, Personalized Medicine Coalition

Emily Kramer-Golinkoff, Co-Founder, Emilys Entourage, cystic fibrosis patient

Bryce Olson, Global Marketing Director, Health and Life Sciences Group, Intel Corporation; stage IV prostate cancer patient

11:10 a.m.

Automating Actionable: How Artificial Intelligence May Chart a Course for Personalized Medicine

Artificial intelligence may help inform personalized medicine in the future by perceiving which genes, proteins and other biological characteristics contribute to human disease. During this session, a diverse panel will discuss how artificial intelligence may accelerate drug development, improve clinical decision support and drive patient outcomes and what that might mean for the future of health care.

MODERATOR | Colin Hill, Chairman, CEO, Co-Founder, GNS Healthcare

Tom Miller, Managing Partner, GreyBird Ventures LLC

Gregg Talbert, Ph.D., Global Head of Digital and Personalized Health Care Partnering, Roche

Darrell M. West, Ph.D., Vice President of Governance Studies and Director of Center for Technology Innovation, Douglas Dillon Chair in Governance Studies, The Brookings Institution

1:40 p.m.

The Lay of the Lab: Exploring the State of the Clinical Laboratory Testing Industry A Keynote Address

SPEAKER | David King, J.D., Chairman, CEO, LabCorp

2:25 p.m.

The Diagnostics Discussion: Evaluating the Extent to Which the Regulatory and Reimbursement Environment for Diagnostic Tests May Help or Hinder Personalized Medicine

The U.S. Food and Drug Administration and the U.S. Centers for Medicare and Medicaid Services have been working for over a decade to develop regulatory and reimbursement pathways that promote the development of innovative diagnostic tests. Many observers, however, believe the current regulatory and reimbursement landscape still limits the field. This panel of business leaders will discuss the extent to which the existing frameworks and proposed policies may help or hinder personalized medicine.

MODERATOR | Joseph V. Ferrara, CEO, Boston Healthcare Associates

Michael Doherty, Senior Vice President, Head of Product Development, Head of Research & Development, Foundation Medicine

Julie Khani, President, American Clinical Laboratory Association

Kimberly Popovits, Chairman of the Board, CEO, President, Genomic Health

Mark P. Stevenson, Executive Vice President, Chief Operating Officer, Thermo Fisher Scientific

3:25 p.m.

Networking Break

Light refreshments provided.

Sponsored By

3:55 p.m.

Examining Policies: Exploring How Emerging U.S. Regulatory Approaches May Help Facilitate Personalized Care Regimens

The U.S. Food and Drug Administration (FDA) remains firmly committed to regulatory strategies designed to advance personalized medicine. During this wide-ranging fireside chat, two senior leaders from government and industry will discuss the agencys latest actions impacting the oversight of personalized medicine products and services. The discussion will cover topics including but not limited to next-generation sequencing, diagnostic test regulation, digital health, and real-world evidence.

MODERATOR | Cynthia A. Bens, Senior Vice President, Public Policy, Personalized Medicine Coalition

Jesse Berlin, Sc.D., Vice President and Global Head of Epidemiology, Johnson and Johnson

Lauren Silvis, J.D., Chief of Staff, Immediate Office of the Commissioner, FDA

4:55 p.m.

Engaging Everyone: Leveraging Diversity and Facilitating Equitable Access to Personalized Care

Advancing a medical paradigm that focuses on the unique characteristics of each patient will require, by definition, that patients from diverse backgrounds participate in the medical studies that advance our understanding of disease. Also critical is the need to ensure that those patients have access to personalized care informed by those studies. During this session, four panelists will discuss the effort to ensure that all patient populations benefit equally from personalized medicine.

MODERATOR | Donna R. Cryer, J.D., President, CEO, Global Liver Institute

Vence L. Bonham, Jr., J.D., Senior Advisor, Director on Genomics and Health Disparities, U.S. National Human Genome Research Institute

Alex J. Carlisle, Ph.D., Chairman, CEO, National Alliance Against Disparities in Patient Health

Adolph P. Falcn, Executive Vice President, National Alliance for Hispanic Health

Edward Tepporn, Executive Vice President, Asian & Pacific Islander American Health Forum

5:55 p.m.

Closing Remarks

SPEAKER | Amy Abernethy, M.D., Ph.D., Chief Medical Officer, Chief Scientific Officer, Senior Vice President, Oncology, Flatiron Health

6:10 p.m.

Departure for the Museum of Fine Arts, Boston

6:30 p.m.

Welcome Reception at the Museum of Fine Arts, Boston

Avenue of the Arts465 Huntington AvenueBoston, MA 02115

Sponsored by

We will convene for cocktails and hors doeuvres at the Boston Museum of Fine Arts immediately after the first day of conference programming. The museum is in walking distance from the Conference Center.

Sponsored by

6:05 p.m.

Sponsored by

The successful implementation of [personalized medicine] will depend on the embrace of [its] principles in the business community.

Raju Kucherlapati, Ph.D.Paul C. Cabot Professor of Genetics, Harvard Medical School

*** Speakers will be added to the schedule on a rolling basis as they are confirmed. ***

7:00 a.m.

Registration and Continental Breakfast

Joseph B. Martin Conference Center at Harvard Medical School77 Avenue Louis Pasteur, Boston, MA 02115

8:00 a.m.

Opening Remarks

SPEAKER | Stephen L. Eck, M.D., Ph.D., Chief Medical Officer, Immatics U.S. Inc; Board Chair, Personalized Medicine Coalition

8:10 a.m.

Pioneering Precision: Inside the Pharmaceutical Industrys Push Toward Personalized Medicine A Fireside Chat

MODERATOR | Meg Tirrell, Reporter, CNBC

Daniel ODay, CEO, Roche Pharmaceuticals

8:55 a.m.

Considering Costs: Evaluating Emerging Pharmaceutical and Insurance Industry Business Models in Personalized Medicine

The pharmaceutical industry is deeply invested in commercializing personalized therapies that must recoup fixed development costs from smaller patient populations covered by health insurance companies that are increasingly concerned about rising health care costs. In that context, this diverse panel will explore the viability of the business model for developing and paying for personalized medicines, tackling issues related to costs, prices, and access.

MODERATOR | Meg Tirrell, Reporter, CNBC

Read more:
2018 Schedule 15th Annual Personalized Medicine Conference

As your doctor, I practice medicine in a different way than you may be used to. As medical practices get larger and suffer under increasing insurance restraints, many have come to lack something very importantpersonal attention. Due to sagging reimbursements by insurance companies and higher operating costs, many practices are forced to see many patients every day. I want to care for you on a more personal level.

By keeping my practice small, I can focus first on who you are as a person instead of your illness or symptoms. And youll see only me not a nurse practitioner or other doctorsso you get the attention you deserve in a caring, warm environment.

My practice is based on a partial concierge or membership medicine model. This allows me to limit the number of patients I see and provide the personalized, comprehensive primary care you cant find in most doctors offices.

If you choose to become a member, for an affordable annual fee you can access same- or next-day unrushed appointments that allow me to address all of your questions and concerns. And because youll have ongoing direct communication with me, sometimes you can avoid an appointment altogether, or even a trip to the Emergency Department.

Not ready to become a member yet? Thats okay. Im still happy to see youjust understand that many of these special service benefits are for members only.

My smaller practice allows me to focus on more than treating problems, but also teaching wellness and prevention with the goal of living a long and healthy life free from disease. See our services.

Our healthcare system is filled with plenty of challenges, but having a doctor who can spend enough time with you shouldnt be one of them. I look forward to providing you the attentive, personalized care you have always hoped to find.

Do you have questions? Please call us at (910) 762-4488. Our Patient Membership Coordinator / Office Manager Linda will be happy to help you.

~ Dr. Steve LiederbachBoard Certified, Internal Medicine

Read more:
Wilmington Adult Medicine Personalized Medicine Membership ...

Sessions and Tracks

Theme:

About Conference:

The 11th International conference onPredictive Preventive and PersonalizedMedicine & Molecular Diagnostics will be held on October 25-26, 2019 at Vancouver, Canada.whichcomprises 18Sessions/Tracksto outline the theme of the conference organized by Conference series LLC LTD. The main aim of the conference is to highlight the achievements and innovations in the various fields of Personalized Medicine across the globe.

Tracks: 1 Paths of Biomarkers

In medication, a biomarker and sub-atomic markers are the quantifiable pointer of the seriousness or vicinity of some infection state. All the more by and large a biomarker is anything that can be utilized as a marker of a specific ailment state or some other physiological condition of a living being Drug-Diagnostic Co-Development. In the present period of stratified solution and biomarker-driven treatments, the centre has moved from forecasts taking into account the conventional anatomic arranging frameworks to direct the decision of treatment for an individual patient to a coordinated methodology utilizing the hereditary cosmetics of the tumour and the genotype of the patient. Genomics and other innovations have to a great extent added to the recognizable proof and the improvement of biomarkers such as Stratification biomarkers in customized pharmaceutical.

Track 2: Clinical Case Reports: Genetics

Customized solution depends on interspecies contrasts. It is proverbial that little contrasts in hereditary make-up can bring about emotional contrasts because of medications or ailment and societal effect of customized pharmaceutical. To express this in more broad terms in any given complex framework, little changes in beginning conditions can bring about drastically diverse results. In spite of human variability and interspecies variety in different species, nonhuman species are still the essential model for finding out information for personalized solution wellbeing change in Human.

Track 3: Life Style Medicine

Life Medicine (LM) is the utilization of way of life mediations in the treatment and administration of infection. LM is turning into the favoured methodology for the counteractive action as well as the treatment of most perpetual sicknesses, including Type-2 Diabetes, Coronary Heart Disease, Hypertension, Obesity, Insulin Resistance Syndrome, Osteoporosis, malignancy prevention. Likewise incorporate Aerobic and Resistance practices for patients with diabetes, Sleep and infection counteractive action, intrinsic inspiration and wellbeing conduct adherence.

Track 4: Preventive Medicine

Preventive Medicine is honed by all doctors to keep their patients sound. It is additionally an exceptional medicinal claim to fame perceived by the American Board of Medical Specialties (ABMS). Preventive Medicine concentrates on the wellbeing of people, groups, and characterized populaces. It is likewise utilized for the treatment for stoutness, visual impairment. The Epidemiology Division applies research strategies to comprehend the examples and reasons for wellbeing and ailment in the populace and to make an interpretation of this learning into projects intended to avert malady. The division has a long history of inclusion in NIH-supported multi-site, longitudinal partner studies, and its personnel manage numerous specialist started, NIH-supported exploration ventures and trials.

Track 5: Personalized Medicine & its Innovation

Personalized Medicine is a developing routine of medication that uses an individual's hereditary profile to guide choices made with respect to the counteractive action, determination, and treatment of ailment. Information of a patient's hereditary profile can offer specialists some assistance with selecting the best possible prescription or treatment and manage it utilizing the correct measurement or regimen. Utilized for the treatment as Personalized growth solution, Diabetes-related sickness: hazard appraisal and administration, Personalized pharmaceutical: New procedures and monetary ramifications, Implications of customized prescription in treatment of HIV, Applications of customized drug in uncommon illnesses, Translational Medicine.

Track 6: Advances in Molecular Diagnostics

Personalized Medicine is a developing routine of medication that uses an individual's hereditary profile to guide choices made with respect to the counteractive action, determination, and treatment of ailment. Information of a patient's hereditary profile can offer specialists some assistance with selecting the best possible prescription or treatment and manage it utilizing the correct measurement or regimen. Utilized for the treatment as Personalized growth solution, Diabetes-related sickness: hazard appraisal and administration, Personalized pharmaceutical: New procedures and monetary ramifications, Implications of customized prescription in treatment of HIV, Applications of customized drug in uncommon illnesses, Translational Medicine.

Track 7: Market Strategies & Challenges In Personalised Medicine

P4 Medicine is an arrangement to profoundly enhance the nature of human life by means of biotechnology. P4 Medicine is a term authored by scholar Leroy Hood, and is another way to say "Predictive, Preventive, Personalized Medicine, and Molecular Medicine." The reason of P4 Medicine is that, throughout the following 20 years, restorative practice will be altered by biotechnology, to deal with a man's wellbeing, rather than deal with a patient's infection. Inner solution or general medication (in Commonwealth countries) is the medicinal claim to fame managing the avoidance, determination, and treatment of grown-up maladies. Crisis solution is a medicinal claim to fame including watch over grown-up and paediatric patients with intense sicknesses or wounds that require quick therapeutic consideration.

Track 9: Novelty in Personalised Medicine

Personalized Medicine is a developing routine of prescription that uses an individual's hereditary profile to guide choices made with respect to the counteractive action, analysis, and treatment of malady. Learning of a patient's hereditary profile can offer specialists some assistance with selecting the correct prescription or treatment and control it utilizing the best possible measurements or regimen. Utilized for the treatment as Personalized malignancy pharmaceutical, Diabetes-related sickness: hazard evaluation and administration, Personalized drug: New procedures and monetary ramifications, Implications of customized medication in treatment of HIV, Applications of customized prescription in uncommon infections, Translational Medicine.

Track 10: Genomics & Personalized Medicine

Genomics is a control in hereditary qualities that applies Recombinant DNA, DNA sequencing techniques, and bioinformatics to grouping, amass, and break down the capacity and structure of genomes. Propels in genomics have set off an insurgency in disclosure based examination to see even the most complex organic frameworks, for example, the mind. The field incorporates endeavours to decide the whole DNA grouping and human genome variation of life forms and fine-scale hereditary mapping. The field additionally incorporates investigations of intragenomic marvels, for example, heterosis, epistasis, pleiotropy and different associations in the middle of loci and all within the genome and met genomics.

Track 11: Genetics of Ebola Outbreak

Arrangement investigation of Ebola infection Genome is the second through the 6th qualities of the Ebola infection (EBO) genome demonstrates that it is sorted out also to rhabdoviruses and paramyxoviruses and is for all intents and purposes the same as Marburg infection (MBG). Researchers utilized genomic sequencing advancements to recognize the starting point and track transmission of the Ebola infection in the ebb and flow flare-up in Africa.

Track 12: Approaches To Stem Cells

Personalized Medicine can be utilized to find out around a man's hereditary cosmetics and to disentangle the science of their tumour. Utilizing this data, specialists want to recognize anticipation, screening, and treatment techniques that might be more successful and cause less symptoms than would be normal with standard medicines. By performing more hereditary tests and examination, specialists might alter treatment to every patient's needs. Making a customized malignancy screening and treatment arrangement incorporates: Determining the odds that a man will create growth and selecting screening techniques to bring down the danger, Matching patients with medications that will probably be compelling and cause less reactions, Predicting the danger of repeat (return of Cancer)

Track 13: Nanotechnology: Future of Personalised Medicine

Nanotechnology ("nanotech") is the control of matter on a nuclear, atomic, and supramolecular scale. The soonest, across the board portrayal of nanotechnology alluded to the specific mechanical objective of accurately controlling particles and atoms for creation of macro scale items, likewise now alluded to as sub-atomic nanotechnology. Uses of pharmaceutical Nano tools, Cell based treatment Molecular systems are the strategies and instrument in Nano innovation and biotechnology.

Track 14: Personalized Drug Therapy

The personalizeddrug is a field of medication that involves foreseeing the likelihood of malady and establishing preventive measures keeping in mind the end goal to either keep the ailment by and large or altogether abatement its effect upon the patient, (for example, by avoiding mortality or constraining dreariness). Methods and measures incorporate New-born screening,Diagnostic testing, Medical bioinformatics, Prenatal testing, Carrier testing, Preconception testing. Infant screening is a general wellbeing program intended to screen babies not long after conception for a rundown of conditions that are treatable, however not clinically clear in the infant period. Pre-birth testing: Prenatal testing is utilized to search for sicknesses and conditions in a hatchling or developing life before it is conceived. This kind of testing is offered for couples who have an expanded danger of having a child with a hereditary or chromosomal issue.

Track 15: Personalized Oncology

The era of personalized oncology medicine has the potential to fulfil the promise of delivering the right dose for the right indication to the right patient at the right time. Imagine your oncologist knowing before he makes a treatment decision how well your cancer may respond to a particular therapy. Tools that enable a more informed treatment decision do exist and may help individualize your cancer care. It is very important for oncologists to keep updated of the latest advancements in oncology as changes in management of cancer are quite common. All fit patients whose cancer progresses and no standard of care treatment options are available should be enrolled in a clinical trial. Personalized medicine is used to learn about a persons genetic makeup and how their tumor grows. Using this data, doctors hope to find prevention, screening, and treatment strategies that may be more effective. They also want to find ones that cause fewer side effects than the standard treatments. By performing more genetic tests, doctors may customize treatment to each patients needs.

Track 16: Immunology Infectious Disease

Clinical immunology is the study of diseases caused by disorders of the immune system. It also involves diseases of other systems, where immune reactions play a part in the pathology and clinical features. Many components of the immune system are actually cellular in nature and not associated with any specific organ but rather are embedded or circulating in various tissues located throughout the body. Immunotherapy is a new class of cancer treatment that works to harness the innate powers of the immune system to fight cancer. Because of the immune system's unique properties, these therapies may hold greater potential than current treatment approaches to fight cancer more powerfully, to offer longer-term protection against the disease, to come with fewer side effects, and to benefit more patients with more cancer types. Scientists believe that for most people, Alzheimer's disease results from a combination of genetic, lifestyle and environmental factors that affect the brain over time. In Parkinsons disease, cells that produce dopamine start to die. Dopamine is a chemical that helps you move normally. There is no known direct cause of Parkinsons. One theory is that it may be hereditary. Other theories say exposure to pesticides and living in rural communities may cause it.

Track 17: Cardiology and Vascular Medicine

The objective of the Cardiac Research is to quicken interpretation of promising new crucial examination revelations for the treatment of heart disappointment and arrhythmias through very much composed clinical trials that exhibit viability and security. Vascular Medicine envelops a wide range of different disease states. As the field of vascular Medicine develops, the extent of illnesses being dealt with changes. Cardiovascular renovating alludes to the adjustments in size, shape, structure and physiology of the heart after damage to the myocardium. The harm is normally because of intense myocardial dead tissue. To portray the expansion in lipoprotein interpretation by hypothyroidism, adipocytes were readied from control and hypothyroid rats. While LPL combination was higher in hypothyroid adipocytes, with no adjustment in mRNA levels, there was no expansion in hormone-touchy lipase (HSL) blend.

Read more here:
Medicine conferences 2019: Personalized | Predictive ...

His groundbreaking work has changed the very ways we consider our health and examine disease. (President Barack Obama)

The future of customized medicine is in your DNA; dont wait until you are sick to learn why. (Dr. Mehmet Oz, author of You: The Owner's Manual)

With fluid prose and compelling narratives, Francis Collins makes modern medical science vivid and accessible. This book sets out hope without hype, and will enrich the mind and uplift the heart. (Jerome Groopman, M.D., Recanati Professor, Harvard Medical School, Author of How Doctors Think)

Mans knowledge of man is undergoing the greatest revolution since Leonardo, and Francis Collins is at the leading edge of it. I am a better doctor today because Dr. Collins was my genetics professor in medical school, and now, the world gets to benefit from his wisdom by reading The Language of Life. (Dr. Sanjay Gupta, Neurosurgeon at Emory University and Chief Medical Correspondent for CNN)

Link:
The Language of Life: DNA and the Revolution in ...

The 14th Annual Personalized Medicine Conference: Preparing for the New Possible will convene the worlds leading researchers, investors, industry executives, policy experts, payers, clinicians, and patient advocates to define the landscape and outlook for personalized medicine in science, business, and policy. Participants will examine the infrastructure and business strategies necessary to overcome scientific obstacles, optimize public policies, and change embedded medical norms as we seek to accelerate investment in and adoption of personalized medicine.

Featured Speakers

Amy P. Abernethy, M.D., Ph.D.

Chief Medical Officer, Chief Scientific Officer

Flatiron Health

Donna R. Cryer, J.D.

President, CEO

Global Liver Institute

Luba Greenwood, J.D.

Strategic Business Development and Corporate Ventures

Verily, an Alphabet Company

David King, J.D.

Chairman, CEO

LabCorp

Daniel P. ODay, M.B.A.

Chief Executive Officer

Roche Pharmaceuticals

Ellen V. Sigal, Ph.D.

Chairperson, Founder

Friends of Cancer Research

Ralph Snyderman, M.D.

James B. Duke Professor of Medicine

Duke University

Keith Stewart, M.B., Ch.B.

Carlson and Nelson Endowed Director, Center for Individualized Medicine

Mayo Clinic

Liisa-Maria Voipio-Pulkki, M.D., Ph.D.

Director General, Chief Medical Officer, Ministry of Social Affairs and Health

Finland

View full List of Speakers

Continued here:
14th Annual Personalized Medicine Conference November 14 ...

Personalized Adult Primary and Preventive Medicine in Denver, ColoradoFloyd Russak, MD with Katie Bunt, MA(left) and Kimberly Boonstra ( right)Personalized MedicineAbout My Practice

I see patients through my personalized medicine membership practice. This personalized approach to primary care health delivery will change how you perceive your health health and engage with me as your doctor.

Read More

My Clinical Assistant, Katie Bunt (above left) and my Executive Assistant, Renee Collishaw (above right) are at your service. They are committed to exceeding your expectations and helping me help you optimize your health.

As a personalized care program member, you'll enjoy the finest in preventive health coupled with breakthrough diagnostics and treatments.

Read More

You're going to love the convenience of our on-site diagnostic screening and laboratory services! No more wasted time and energy running around town from place to place to meet your healthcare needs.

Read More

Dr. Russak is committed to providing all of his personalized membership patients with the finest in preventive care, breakthrough diagnostics and treatments, rapid access appointments and telemedicine.

He believes that appointments should start on time and last as long as necessary, and that you should have access to a dedicated physician invested in your well-being 24 hours a day, 365 days a year.

At Russak Personalized Medicine, our priority is to deliver quality care to informed patients in a comfortable and convenient setting.

Quality Care

When you have needs for medical care, you need to turn to a doctor who listens and responds an experienced doctor who knows the field and can effectively diagnose and treat your needs a friendly physician who counsels you on the best ways to maintain and improve your health. Our physician(s) meet all these criteria. Plus, you benefit from a dedicated team of trained professionals who give you the individualized attention you deserve.

Informed Patients

Russak Personalized Medicinebelieves that informed patients are better prepared to make decisions regarding their health and well-being.

Comfortable, Convenient Setting

The best care in the world doesnt mean anything if you cant access it. At Russak Personalized Medicine, we strive to make our Greenwood Village office as efficient and convenient as possible. Included in these web pages is information aboutRussak Personalized Medicines office, including our Greenwood Village location, maps, directions, hours, insurance policies, and appointment scheduling. You can even email a request for an appointment right here! We hope you find this website useful and invite you to contact us with your questions at any time.

Read the original here:
Russak Personalized Medicine - Primary Care Physician in ...

Just as every person is unique, so is every cancer. At the Knight Cancer Institute, were dedicated to finding what makes each cancer unique and providing individually tailored and targeted treatments.

Our pioneering work in personalized medicine ultimately led to the discovery of one of the worlds first targeted cancer drugs, Gleevec, by Dr. Brian Druker at the OHSU Knight Cancer Institute. Gleevec truly revolutionized the way cancer is treated and works by zeroing in and eliminating specific cancer-causing cells, while avoiding serious damage to other non-cancerous ones. This major turning point in the treatment of cancer has led us to expand our focus on delivering personalized care by recruiting the very best and most experienced clinicians and researchers from across the country. But we wont stop there! Through our efforts in cancer research, diagnostics, drug development and treatments, we continue to lead the way in the field of personalized care.

Dr. Druker has stated that Our goal going forward is to advance science so that someday there will be a targeted therapy to shut down every form of cancer. At the OHSU Knight Cancer Institute, each of us believes in a world without cancer and has a mission to end this disease in our lifetime.

Asleadersinthefieldofpersonalizedmedicine,weare investing in:

At the Knight Cancer Institute our physicians, pathologists, researchers and other member of the team work together to bring each patient the best personalized care available. For us it truly is:

See more here:
Personalized Cancer Medicine | Knight Cancer Institute | OHSU

Sunday2:00 pm - 8:00 pm

Arrival and Check-in

Dinner

Introductory Comments by GRC Site Staff / Welcome from the GRC Chair

Discussion Leader: Chih-Ming Ho (University of California, Los Angeles, USA)

Introduction by Discussion Leader

Dean Ho (BIGHEART, National University of Singapore, Singapore)

Discussion

Edward Kai-Hua Chow (Cancer Science Institute of Singapore, National University of Singapore, Singapore)

Discussion

Bin Tean Teh (National Cancer Centre Singapore, Singapore)

Discussion

General Discussion

Breakfast

Discussion Leader: Mien-Chie Hung (University of Texas MD Anderson Cancer Center, USA)

Introduction by Discussion Leader

Wei Zhang (Comprehensive Cancer Center, Wake Forest University, USA)

Discussion

Group Photo / Coffee Break

Chuan He (University of Chicago, USA)

Discussion

Jindan Yu (Northwestern University, USA)

Discussion

General Discussion

Lunch

Free Time

Poster Session

Dinner

Discussion Leader: Rita Yen-Hua Huang (Taipei Medical University, Taiwan)

Introduction by Discussion Leader

Ye-Guang Chen (Tsinghua University, China)

Discussion

Bradley Cairns (University of Utah, USA)

Discussion

General Discussion

Breakfast

Discussion Leader: Wei Jia (University of Hawaii Cancer Center, USA)

Introduction by Discussion Leader

Neal Rosen (Memorial Sloan Kettering Cancer Center, USA)

Discussion

Coffee Break

Van-Dang Chi (Ludwig Cancer Research, USA)

Discussion

Shengfang Jin (Agios Pharmaceuticals Inc, USA)

Discussion

General Discussion

Lunch

Poster Session

Discussion Leader: Tony S.K. Mok (Chinese University of Hong Kong, Hong Kong SAR China)

Introduction by Discussion Leader

Patrycja Nowak-Sliwinska (University of Geneva, Switzerland)

Discussion

Hong Wu (School of Life Sciences, Peking University, China)

Discussion

Jonathan Keats (Translational Genomics Research Institute (TGen) / City of Hope, USA)

Discussion

General Discussion

Dinner

Breakfast

Discussion Leader: Priscilla Kelly (Science, AAAS, USA)

Introduction by Discussion Leader

Pui-Yan Kwok (Institute of Biomedical Sciences, Academia Sinica, Taiwan)

Discussion

Sridhar Mani (Albert Einstein College of Medicine, USA)

Discussion

Coffee Break

Christiane Querfeld (Cutaneous Lymphoma Program, City of Hope, USA)

Discussion

Irene O.L. Ng (The University of Hong Kong, Hong Kong SAR China)

Discussion

General Discussion

Lunch

Free Time

Poster Session

Dinner

Business MeetingNominations for the Next Vice Chair; Fill in Conference Evaluation Forms; Discuss Future Site and Scheduling Preferences; Election of the Next Vice Chair

Discussion Leader: Richard Weinshilboum (Mayo Clinic, USA)

Introduction by Discussion Leader

James Lee (University of Pittsburgh School of Medicine, USA)

Discussion

Steven Offer (Mayo Clinic, USA)

Discussion

Liewei Wang (Mayo Clinic, USA)

Discussion

General Discussion

Breakfast

Discussion Leader: Chien-Tsun Kuan (Development Center for Biotechnology, Taiwan)

Introduction by Discussion Leader

Arjan Griffioen (VU University Medical Center, The Netherlands)

Discussion

John Williams (Beckman Research Institute, City of Hope, USA)

Discussion

Coffee Break

Xianting Ding (Institute for Personalized Medicine, Shanghai Jiao Tong University, China)

Discussion

Ali Zarrinpar (Division of Transplantation and Hepatobiliary Surgery, University of Florida College of Medicine, USA)

Discussion

General Discussion

Lunch

Free Time

Read more here:
2018 Personalized Medicine Conference GRC

Personalized medicine relies on tests to help determine an individuals response to certain medications.

Personalized medicine takes into account your unique genetic makeup. Unlike "genetic medicine," which is directed at such inherited diseases as sickle cell anemia, personalized medicine can help your doctor tailor treatment for conditions such as heart disease and deep vein thrombosis. This enables him/her to focus on prevention, detection and early intervention.

Your genetic makeup also affects which medicines work best for youand how you respond to them. Your doctor can prescribe targeted treatment based on both:

We offer two such tests, which represent the forefront of personalized medicine. They can determine your response to two of the most widely prescribed drugs.

Marketed as Coumadin and Jantoven, warfarin thins the blood to help prevent and treat deep vein thrombosis, stroke, heart attack, atrial fibrillation and other diseases of the arteries and veins. The right dosage is crucial. Too low a dose could increase the risk of a life-threatening blood clot. Too high a dose could increase bleeding risk. Plus, your response to a specific dose can vary widely. We offer the AccuType Warfarin test to help your physician determine the appropriate dosage based on your genetic information.

Marketed as Plavix, clopidogrel is another blood thinner. The AccuType CP test identifies if youre unlikely to respond well to the drug and therefore at increased risk for stroke or heart attack. It also identifies if youre likely to be overly sensitive to the drug and therefore at increased risk for bleeding episodes.

Personalized medicine, including these two laboratory tests, can help make possible:

The rest is here:
Health and Wellness : Personalized Medicine

It's time to accelerate medical progress.

Since its inception, The Jackson Laboratory has led the discovery of causes, treatments and cures for some of humankind's most devastating genetic diseases. Today, we are speeding the path of discovery from the laboratory bench to clinical care. We are combining the skills and knowledge of our scientists with our institutional strengths in disease modeling and bioinformatics, connecting genetics to genomics, and using our unparalleled knowledge of mouse models of disease to understand the human condition.

JAX research programs are leading efforts to improve human health worldwide.

Addiction is a chronic illness, with genetic, environmental and social aspects. JAX researchers are at the forefront of understanding the genetic factors involved in individuals vulnerability to addiction.

JAX researchers are using genomic technologies and specialized mouse models to decipher the changes that occur as a consequence of aging in order to extend our health span, delay age-related health issues, repair damaged organs and improve our quality of life.

Using genomic technologies and specialized mouse models to develop preventative therapies, JAX scientists aim to stop Alzheimers before it starts.

Driven by the desire to eradicate cancer, we are leading the future of cancer treatments by combining computational expertise with our unparalleled knowledge of mouse genetics.

JAX researchers investigate the processes that lead to failure to produce insulin in type 1 diabetes and loss of insulin production in type 2 diabetes.

JAX researchers are exploring the effect on health and disease of the microorganisms that outnumber human cells 10 to 1.

About 80 percent of rare diseases are genetic in origin, about half affect children, many are fatal, and very few have cures.

More here:
Personalized Medicine | The Jackson Laboratory

Immuno-oncology (I-O) relates to the recruitment of ones own immune system for the treatment and eradication of cancer. Remarkable clinical results with immuno-oncology treatments within the past 5 years, in particular with immune checkpoint inhibitor drugs, have catapulted the field onto center stage for consideration by patients, clinicians, academic investigators as well as pharmaceutical and biotech companies.

The I-O premise is relatively straightforward to unleash the killing potential due to the exquisite specificity of a patients T lymphocytes (predominantly CD8 T cells) to target and eliminate cancer cells throughout the body. Administration of immune checkpoint inhibitor drugs, such as monoclonal antibodies (e.g., Keytruda, Opdivo, Tecentriq) that interfere with the T cell immune restraints imposed by PD-1 : PD-L1 receptor interactions have dramatically realized the potential to yield rapid and durable clinical responses in those patients whose T cells have already been trained, yet silenced, to eliminate the tumors. These drugs, while highly effective for patients with different cancers (e.g., melanoma, lung and bladder cancers), are limited to benefit those 20-30% of patients whose immune system shows evidence of pre-existing cancer recognition.

On closer scrutiny of the T cell immune responses in patients that benefit from monotherapy treatment with immune checkpoint inhibitordrugs, significant evidence has been generated that the patients CD8 T cells likely target protein mutations (antigens) unique to the tumor (neo-antigens). As shown in the figures below, patients whose tumors harbored a greater collection of unique mutations (high nonsynonymous burden; neo-antigen burden) were significantly more likely to benefit clinically from immune checkpoint anti-PD-1 drug monotherapy. This means that the patients already had a collection of CD8 T cells with the ability to recognize peptides derived from these neo-antigens presented to the immune system on the HLA receptors on tumors (neo-epitopes). Since these neo-epitopes are only displayed on the surface of tumor cells, patient T cells that target neo-epitopes should only kill tumor cells. Unleashing the patients neo-epitope specific T cells is, therefore, likely responsible for the rapid and durable clinical benefits seen in some patients upon administration of immune checkpoint inhibitor drugs.

The next wave in immuno-oncology success will depend on initiating highly specific T cell immune recognition of cancers. Based on the current evidence, unleashing a tsunami of T cells that recognize and kill cancer cells displaying patient-specific mutations (neo-epitopes) holds great potential to significantly increase the number of cancer patients that will benefit from I-O therapies.

PACT Pharma is dedicated to synthesizing a tsunami of neo-epitope targeted T cells and producing a personalized adoptive cell therapy designed to benefit each individual cancer patient (as outlined in the diagram below). The neo-epitope targeting is engineered into the patients own T cells (autologous T cells) for programming to seek out, infiltrate into the tumor and kill the tumor cells displaying the unique neo-epitopes. In essence, PACT Pharma is engineering next generation synthetic tumor-infiltrating lymphocytes (synthetic TILs), tailored for each patients cancer with highly efficient turnaround in manufacturing from tumor biopsy to re-infusion of autologous synthetic TILs back into the patient.

Our proprietary approach, the imPACTTM isolation technology, utilizes a highly sensitive nanoparticle and microfluidic engineering system and fabricated chips to identify and to isolate very rare T cells in patients that already recognize the cancer neo-epitopes. The figure below reveals that these T cells can be interrogated for their specificity of neo-epitope recognition. Using a barcode system on the nanoparticle, together with a series of three different fluor-bound DNA sequences, the neo-epitope specificity of each CD8 T cell trapped in the chip is translated (e.g. T cell #3 yielded a signal of yellow-red-green, which translates to neo-epitope #12 in the table below).

Following imPACTTMisolation, our machine learning algorithms define the most relevant neo-epitope (NeoE) specific CD8 T cells for therapeutic benefit, from which we extract the T cell receptor (TCR) sequences for PACT TCR-T product development. Using (non-viral) precision genome engineering, the NeoE-targeted TCR sequences replace the endogenous TCR of fresh CD8 and CD4 T cells collected from that same patients peripheral blood (autologous NeoE TCR engineered into autologous fresh T cells) followed by minimal expansion in preparation for re-infusion into the patient. These patient-specific TCR-T cells are formulated to immediately kill all neoantigen-expressing tumors, together with a deep reservoir of ready-to-go TCR-T cells for long term persistence and capable of rapid expansion to prevent future cancer recurrence.

In summary, PACT Pharma is engineering autologous synthetic TILs, which, when administered into the patient, are designed as a tsunami of tumor-specific T cells capable of rapid elimination of cancer throughout the body for durable clinical benefit. This is the promise of next-generation immuno-oncology: to unleash the patients immune system to eradicate cancer

Continued here:
Personalized Medicine | PACT Pharma, Inc.

Product Options:"Ellie's idea of testing your blood to know how to optimize your own nutrition--not anyone's else's--just makes sense. And it works." Vicki Nassif, DDSYFH uses its 40 year data base to compute your optimum rangeand determine your risk factors, NOT justtell you that yourblood test scores are in the lab normal range.Early detection of disease (found by YFH's database) is the key to protecting your health.

"Ellie shows that individuals have distinctive Personal Normal scores that are in a much more narrow range than the laboratory's "normals". This tool for early detection of disease is the key to preventing illness." Dan C. Dantini, MD

YFH provides a blood test kit with: every tube labeledfor accuracy, shipping materials, doctor order, draw siteset up, and your blood results electronically fed fromthe exact equipment YFH stipulates. (Most blood test companies JUST provide the doctor's order.) Also, your blood test results are triple checked and scores can always be compared because YFH controls the test protocol and uses the best equipment each time. Extra serum is collected andfrozen so you can be notified if additional tests are neededto clarify a suspicious score.FREE group telephone test explanations are held regularly.In addition, YFH has a program for international orders (please call or email for details).YFH's trained customer service representatives listen and help you choose thebest group of testsfor your budget. HealthPrint+results include a 200 page guide and YFH's power foods list which includes food and nutritional suggestions customized to your scores. However, we do not sell supplements so there is no conflict of interest. Why not take control of your health today!

Read the original post:
Your Future Health